Iferanserin (INN; VEN-309) is a drug which acts as a selective 5-HT2A receptor antagonist.[1] It is under development as an intra-rectal formulation for the treatment of hemorrhoid disease, and as of February 2012, is in phase IIb clinical trials.[1]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H28N2O |
Molar mass | 348.490 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit